Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals

This article was originally published here

Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said: “Anteros Pharmaceuticals

The post Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply